Clinical Pharmacokinetics

, Volume 47, Issue 3, pp 203–216 | Cite as

Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban — an Oral, Direct Factor Xa Inhibitor — in Patients Undergoing Major Orthopaedic Surgery

  • Wolfgang Mueck
  • Bengt I. Eriksson
  • Kenneth A. Bauer
  • Lars Borris
  • Ola E. Dahl
  • William D. Fisher
  • Michael Gent
  • Sylvia Haas
  • Menno V. Huisman
  • Ajay K. Kakkar
  • Peter Kälebo
  • Louis M. Kwong
  • Frank Misselwitz
  • Alexander G. G. Turpie
Original Research Article

Abstract

Background: There is a clinical need for novel oral anticoagulants with predictable pharmacokinetics and pharmacodynamics. Rivaroxaban is an oral direct Factor Xa (FXa) inhibitor in clinical development for the prevention and treatment of thromboembolic disorders. This analysis was performed to characterize the population pharmacokinetics and pharmacodynamics of rivaroxaban in patients participating in two phase II, double-blind, randomized, active-comparator-controlled studies of twice-daily rivaroxaban for the prevention of venous thromboembolism after total hip- or knee-replacement surgery.

Methods: Sparse blood samples were taken from all patients participating in the studies (n = 1009). In addition, a subset of patients in the hip study (n = 36) underwent full profiling. Rivaroxaban plasma concentrations, FXa activity and the prothrombin time were determined. Nonlinear mixed-effects modelling was used to model the population pharmacokinetics and pharmacodynamics of rivaroxaban.

Results: An oral one-compartment model described the population pharmacokinetics of rivaroxaban well. On the first postoperative day only, categorization of patients as slow or fast absorbers as a tool to address variability in absorption improved the fit of the model. Clearance of rivaroxaban was lower and more variable on the first postoperative day, and so time was factored into the model. Overall, the only major difference between the models for the hip study and the knee study was that clearance was 26% lower in the knee study, resulting in approximately 30% higher exposure. Residual variability in the models was moderate (37% and 34% in the hip and knee studies, respectively). Plasma concentrations of rivaroxaban increased dose dependently. Pharmacokinetic parameters that were estimated using the models agreed closely with results from full-profile patients in the hip study, demonstrating that rivaroxaban pharmacokinetics are predictable. The pharmacokinetics of rivaroxaban were affected by expected covariates: age affected clearance in the hip study only, haematocrit (on the first postoperative day only) and gender affected clearance in the knee study only, and renal function affected clearance in both studies. Bodyweight affected the volume of distribution in both studies. However, the effects of covariates on the pharmacokinetics of rivaroxaban were generally small, and predictions of ‘extreme’ case scenarios suggested that fixed dosing of rivaroxaban was likely to be possible. FXa activity and the prothrombin time were both affected by surgery, probably because of perioperative bleeding and intravenous administration of fluids; therefore, time was included in the pharmacodynamic models. In both studies, FXa activity correlated with rivaroxaban plasma concentrations following a maximum effect model, whereas prothrombin time prolongation correlated following a linear model with intercept. The slope of the prothrombin time prolongation correlation was 3.2 seconds/(100 μg/L) in the hip study and 4.2 seconds/(100 μg/L) in the knee study. Both pharmacodynamic models in both studies demonstrated low residual variability of approximately 10%.

Conclusion: This population analysis in patients undergoing major orthopaedic surgery demonstrated that rivaroxaban has predictable, dose-dependent pharmacokinetics that were well described by an oral one-compartment model and affected by expected covariates. Rivaroxaban exposure could be assessed using the prothrombin time, if necessary, but not the international normalized ratio. The findings suggested that fixed dosing of rivaroxaban may be possible in patients undergoing major orthopaedic surgery.

References

  1. 1.
    Ansell J, Bergqvist D. Current options in the prevention of thromboembolic disease. Drugs 2004; 64: 1–5PubMedCrossRefGoogle Scholar
  2. 2.
    Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59–7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 412–21PubMedCrossRefGoogle Scholar
  3. 3.
    Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59–7939 — an oral, direct Factor Xa inhibitor — after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61: 873–80PubMedCrossRefGoogle Scholar
  4. 4.
    Kubitza D, Becka M, Zuehlsdorf M, et al. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59–7939) in healthy subjects. J Clin Pharmacol 2007; 47: 218–26PubMedCrossRefGoogle Scholar
  5. 5.
    Kubitza D, Beck M, Mueck W, et al. The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban [abstract no. 905]. Blood (ASH Annual Meeting Abstracts) 2006; 108 (11) [online]. Available from URL: http://abstracts.hematologylibrary.org/content/voll08/issue11/ [Accessed 2008 Jan 23]
  6. 6.
    Halabi A, Maatouk H, Klause N, et al. Effect of renal impairment on the pharmacology of rivaroxaban (BAY 59-7939) — an oral, direct Factor Xa inhibitor [abstract no. 913]. Blood (ASH Annual Meeting Abstracts) 2006; 108 (11) [online]. Available from URL: http://abstracts.hematologylibrary.org/content/voll08/issue11/ [Accessed 2008 Jan 31]
  7. 7.
    Kubitza D, Becka M, Voith B, et al. Effect of enoxaparin on the safety, tolerability, pharmacodynamics and pharmacokinetics of BAY 59-7939 — an oral, direct Factor Xa inhibitor [abstract no. P1704]. J Thromb Haemost 2005; 3 Suppl. 1 [online]. Available from URL: http://www.blackwellpublishing.com/isth2005/abstract.asp?id=47212 [Accessed 2008 Jan 31]
  8. 8.
    Kubitza D, Becka M, Mueck W, et al. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban — an oral, direct Factor Xa inhibitor — are not affected by aspirin. J Clin Pharmacol 2006; 46: 981–90PubMedCrossRefGoogle Scholar
  9. 9.
    Kubitza D, Becka M, Mueck W, et al. Rivaroxaban (BAY 59-7939) — an oral, direct Factor Xa inhibitor — has no clinically relevant interaction with naproxen. Br J Clin Pharmacol 2007; 63: 469–76PubMedCrossRefGoogle Scholar
  10. 10.
    Kubitza D, Becka M, Zuehlsdorf M, et al. No interaction between the novel, oral direct Factor Xa inhibitor BAY 59-7939 and digoxin [abstract no. 11]. J Clin Pharmacol 2006; 46: 702Google Scholar
  11. 11.
    Dahl OE. Orthopaedic surgery as a model for drug development in thrombosis. Drugs 2004; 64 Suppl. 1: 17–25PubMedCrossRefGoogle Scholar
  12. 12.
    Turpie AG, Fisher WD, Bauer KA, et al. BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 2005; 3: 2479–86PubMedCrossRefGoogle Scholar
  13. 13.
    Eriksson BI, Borris L, Dahl OE, et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006; 4: 121–8PubMedCrossRefGoogle Scholar
  14. 14.
    Eriksson BI, Borris LC, Dahl OE, et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006; 114: 2374–81PubMedCrossRefGoogle Scholar
  15. 15.
    Mueck W, Becka M, Kubitza D, et al. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban — an oral, direct Factor Xa inhibitor — in healthy subjects. Int J Clin Pharmacol Ther 2007; 45: 335–44PubMedGoogle Scholar
  16. 16.
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41PubMedCrossRefGoogle Scholar
  17. 17.
    Kennedy JM, Riji AM. Effects of surgery on the pharmacokinetic parameters of drugs. Clin Pharmacokinet 1998; 35: 293–312PubMedCrossRefGoogle Scholar
  18. 18.
    Eriksson UG, Mandema JW, Karlsson MO, et al. Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis. Clin Pharmacokinet 2003; 42: 687–701PubMedCrossRefGoogle Scholar
  19. 19.
    Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005; 45: 555–63PubMedCrossRefGoogle Scholar
  20. 20.
    Troconiz IF, Tillmann C, Liesenfeld KH, et al. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery. J Clin Pharmacol 2007; 47: 371–82PubMedCrossRefGoogle Scholar
  21. 21.
    Weinz C, Schwartz T, Pleiss U, et al. Metabolism and distribution of [14C]BAY 59-7939 — an oral, direct Factor Xa inhibitor — in rat, dog and human [abstract no. 196]. Drug Metab Rev 2004; 36 Suppl. 1: 98Google Scholar
  22. 22.
    Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 204S–33SPubMedCrossRefGoogle Scholar
  23. 23.
    Liesenfeld KH, Schafer HG, Troconiz IF, et al. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol 2006; 62: 527–37PubMedCrossRefGoogle Scholar
  24. 24.
    Tobu M, Iqbal O, Hoppensteadt DA, et al. Effects of a synthetic factor Xa inhibitor (JTV-803) on various laboratory tests. Clin Appl Thromb Hemost 2002; 8: 325–36PubMedCrossRefGoogle Scholar
  25. 25.
    Tobu M, Iqbal O, Hoppensteadt D, et al. Anti-Xa and anti-IIa drugs alter international normalized ratio measurements: potential problems in the monitoring of oral anticoagulants. Clin Appl Thromb Hemost 2004; 10: 301–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • Wolfgang Mueck
    • 1
  • Bengt I. Eriksson
    • 2
  • Kenneth A. Bauer
    • 3
  • Lars Borris
    • 4
  • Ola E. Dahl
    • 5
  • William D. Fisher
    • 6
  • Michael Gent
    • 7
  • Sylvia Haas
    • 8
  • Menno V. Huisman
    • 9
  • Ajay K. Kakkar
    • 5
    • 10
  • Peter Kälebo
    • 2
  • Louis M. Kwong
    • 11
  • Frank Misselwitz
    • 1
  • Alexander G. G. Turpie
    • 7
  1. 1.Bayer HealthCare AGWuppertalGermany
  2. 2.Sahlgrenska University Hospital/ÖstraGothenburgSweden
  3. 3.Beth Israel Deaconess Medical CenterBostonUSA
  4. 4.Aarhus University HospitalAarhusDenmark
  5. 5.Thrombosis Research InstituteLondonUK
  6. 6.McGill University Health CentreMontrealCanada
  7. 7.Department of MedicineHHS-General HospitalHamiltonCanada
  8. 8.Institute for Experimental Oncology and Therapy ResearchMunichGermany
  9. 9.Leiden University Medical CenterLeidenThe Netherlands
  10. 10.Barts and the London School of MedicineLondonUK
  11. 11.Harbor-UCLA Medical CenterTorranceUSA
  12. 12.Clinical PharmacologyBayer Health-Care AGWuppertalGermany

Personalised recommendations